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Abstract
Purpose: hERG1 channels are aberrantly expressed in several types of human cancers, where they affect
different aspects of cancer cell behavior. A thorough analysis of the functional role and clinical significance
of hERG1 channels in gastric cancer is still lacking.
Experimental Design: hERG1 expression was tested in a wide (508 samples) Italian cohort of surgically
resected patients with gastric cancer, by immunohistochemistry and real-time quantitative PCR. The
functional link between hERG1 and the VEGF-A was studied in different gastric cancer cell lines. The
effects of hERG1 and VEGF-A inhibition were evaluated in vivo in xenograft mouse models.
Results:hERG1was positive in 69%of the patients and positivity correlatedwith Lauren’s intestinal type,
fundus localization of the tumor, G1–G2 grading, I and II tumor—node—metastasis stage, and VEGF-A
expression. hERG1 activity modulated VEGF-A secretion, through an AKT-dependent regulation of the
transcriptional activity of the hypoxia inducible factor. Treatment of immunodeficient mice xenografted
with human gastric cancer cells, with a combination of hERG1 blockers and anti-VEGF-A antibodies,
impaired tumor growth more than single-drug treatments.
Conclusion: Our results show that hERG1 (i) is aberrantly expressed in human gastric cancer since its
early stages; (ii) drives an intracellular pathway leading to VEGF-A secretion; (iii) can be exploited to identify
a gastric cancer patients’ group where a combined treatment with antiangiogenic drugs and noncardiotoxic
hERG1 inhibitors could be proposed. Clin Cancer Res; 20(6); 1502–12. !2014 AACR.
Introduction
Despite the decrease in gastric cancer mortality observed
worldwide in the last decades, gastric cancer is still an
important health issue (1). Standard chemotherapy, both
in resectable and advanced disease, has limited efficacy,
therefore the identification of new molecular markers to
improve prognosis as well as of mechanisms and targets for
therapeutic interventions, are needed (2).
In the last years, ion channels and transporters have been
demonstrated to control many key aspects of neoplastic
progression in different types of human cancers (3–5).
Moreover, blocking the activity of either ion channels or
transporters impairs the growth of some tumors, both in
vitro and in vivo. These observations have opened a newfield
for pharmaceutical research in oncology (6).
In this context, several research groups provided evi-
dences that a pivotal role in cancer progression is exerted by
Kþ channels of the ether !a-go-go gene (EAG) family (7). In
particular, we demonstrated that Kþ channels encoded by
the human ether !a-go-go-related gene 1 (hERG1) are over- and
mis-expressed inhuman cancers of different histogenesis. In
such cells, hERG1 channels control several aspects of the
neoplastic cell physiology (7, 8). More importantly, in this
view of the purpose of this article, hERG1 activity is mod-
ulated by hypoxia (9) and has an important role in
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regulating VEGF-A secretion in astrocytomas (10). More-
over, hERG1 modulates VEGF-receptor-1 (FLT-1)-induced
cell migration and signaling in acute myeloid leukemias
(11).
The expression of hERG1 in gastric cancer has been
addressed by different groups. It was first shown that hERG1
channels are functionally expressed in gastric cancer cell
lines, where they are critical for in vitro cell proliferation (12,
13). More recently, hERG1 expression was found to corre-
late with tumor grading, TNM stage, and lymph node
involvement (14) as well as serosal and venous invasion
(15), in 2 small cohort retrospective studies. Despite these
results, consistent evidences about hERG1 clinical signifi-
cance in gastric cancer and its prognostic impact are still
lacking.
The purpose of this article is to better analyze the
expression of hERG1 channels, as well as its prognostic
role in a wide Italian cohort of gastric cancer, with peculiar
emphasis to its functional correlation with VEGF-A. More-
over, the possible therapeutic effect of combining hERG1
and VEGF-A–targeting treatments in gastric cancer was also
investigated.
Materials and Methods
Patients and specimens
Tissue samples (n ¼ 190) were obtained after informed
written consent from patients who underwent radical
surgery for primary gastric cancer at the Department of
Surgery and Translational Medicine, University of Flor-
ence and the General Surgery and Surgical Oncology,
Azienda Ospedaliero-Universitaria, Careggi. Samples
were collected as in ref. 16. All samples were divided
into 3 aliquots, 1 immediately fixed in formalin, 1 frozen
in liquid nitrogen for storage, and the other stored in
RNAlater (Ambion).
Moreover, a multicenter cohort of gastric cancer archival
samples (n ¼ 389) mainly assembled as tissue microarrays
was collected as specified in Supplementary Data. Patients
were enrolled between 1987 and 2008 and their lesions
encompassed all disease stages. Subjects who had under-
gone preoperative radiotherapy or chemotherapy were
excluded. Considering both the prospective and the retro-
spective cohorts, 579 sampleswere analyzed.Diagnosis and
histologic grading were assessed using standard criteria by
experienced pathologists (L. Messerini, A. Tomezzoli, C.
Vindigni, and L. Saragoni).
Immunohistochemistry
hERG1 and VEGF expression were retrospectively tested
in 579 patients by immunohistochemistry (IHC), per-
formed as previously reported (17) using the antibodies
reported in Supplementary Table S1. Stained sections were
analyzed as in ref. (17).
Statistical analysis
To avoid the exclusion of cases with missing data, the
multiple imputationmethodwas used (10 imputations; see
Supplementary Data for further details). Statistical analyses
were performed by L. Boni using SAS version 9.2 (SAS
Institute).
DNA methylation studies
The DNA methylation status of the CpG islands located
within the hERG1A promoter (18) and next to its transcrip-
tion starting site (TSS) was determined by chemical mod-
ification of unmethylated cytosine to uracil and subsequent
PCR using primers specific for either methylated or
unmethylated DNA. For details see Supplementary Data.
To amplify the promoter and the TSS regions of the hERG1A
gene on the sodium bisulfite–treated DNA sample, specific
primer (designed with the MethPrimer software) were used
(Supplementary Table S2).
RNA extraction and reverse transcription
Total RNA was extracted using TRizol (Invitrogen), fol-
lowing the manufacturer’s protocol. Reverse transcription
(RT) was performed using 1 mg of total RNA and Superscript
II (Invitrogen), according to themanufacturer’s instructions
but avoiding the use of reducing agents (dithiotreithol).
Real-time quantitative PCR
RNA extraction, reverse transcription, and real-time
quantitative PCR (RQ-PCR) were performed as in ref. 11.
Further details are reported in Supplementary Data. The
primer sequences are reported in Supplementary Table S2.
For mRNA stability experiments, data were normalized to
18S rRNA,whose net amount is not affected by actinomycin
D (ActD) treatment.
Cell cultures
All the cell lines used and culture conditions are listed in
Supplementary Table S3.
Translational Relevance
In gastric cancer, standard chemotherapy, both in
resectable and advanced disease, has limited efficacy. In
search of molecular markers to improve prognosis and
identify novel therapeutic interventions, we studied
hERG1 channels in a wide cohort of gastric cancer
samples collected from different Italian centers. We
provide evidence that hERG1 is expressed in themajority
of samples, especially in Lauren’s intestinal type. hERG1
was expressed since the early stages of gastric cancer
progression and could identify patients with high-risk
T1 stage. We also show that hERG1 regulates VEGF-A
secretion in gastric cancer, and that a combined treat-
ment of mice xenografted with gastric cancer cells with
hERG1 blockers and anti–VEGF-A antibodies has an
additive antitumoral effect. Thus, there is the potential
for a personalized treatment combining noncardiotoxic
hERG1 blockers and antiangiogenic drugs in patients
with hERG1-positive gastric cancer.
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VEGF-A secretion
Cellswere seeded into 24-well cell culture plates at 2# 105
cells/mL in standard culture medium. After 24 hours, the
mediumwas removed and 0.5 mL of Optimem (Gibco) was
added. After an additional 24 hours incubation, themedium
was collected and VEGF-Ameasured using the DuoSet ELISA
Development System (R&D Systems). Cells were recovered
and counted to normalize the VEGF-A secretion data. When
needed, the following inhibitors reported in parentheses
were added along with Optimem: (i) hERG1-specific inhi-
bitors [E4031 or WAY 123,398 (WAY), at the final concen-
tration 40 mmol/L, as described in ref. 10]; (ii) the PI3K/Akt
inhibitor LY294002 (10 mmol/L; Sigma), or the PI3K/Akt
inhibitor perifosine (20 mmol/L, kindly provided by Dr. A.
Martelli, University of Bologna).
Cell transfection
Transient transfections were commonly performed using
the Lipofectamine 2000 reagent (Invitrogen) for siRNAs.
For the transfection of Akt1 and Akt2, the Hiperfect Trans-
fection Reagent (Qiagen) was used following the manufac-
turer’s instructions.
Hypoxia-inducible factor activity
Hypoxia-inducible factor (HIF) activity was measured
using cells transfected with the hypoxia responsive element
luciferase reporter gene vector, kindly provided by Dr. A.
Giaccia (Stanford University School of Medicine, Stanford,
CA), andmeasuring luciferase activity. For detailed descrip-
tion, see Supplementary Data.
In vivo experiments on nu/nu mice
All in vivo experiments are extensively described in Sup-
plementary Data. All experimentation on live vertebrates
described in this articlewas approved by the ItalianMinistry
of Health (document no. 140/2009-B).
Results
Analysis of hERG1 expression in primary gastric cancer
To define the clinical significance of hERG1 in gastric
cancer, we first carefully evaluated its expression and func-
tion in both gastric cancer primary samples and gastric
cancer cell lines.
hERG1 protein expression was determined through IHC
in gastric cancer primary samples, analyzing both the tumor
tissue and the adjacent normal gastric mucosa (Fig. 1). No
hERG1 immunostaining was detected in the lining epithe-
lium of the normal mucosa (Fig. 1A). In some samples, in
which fundic glands were present, we detected hERG1
positivity in parietal cells (Fig. 1B, see arrows). A strong
anddiffuse hERG1 immunoreactivitywas detected in tumor
samples, with a specific expression in neoplastic epithelial
cells. This was more evident in Lauren’s intestinal type (Fig.
1C), whereas diffuse type gastric cancer were negative to
hERG1 staining (Fig. 1D). Figure 1E–H show the hERG1
staining in gastric cancer cases of different grading and stage,
whereas low-magnification pictures in which hERG1 focal
expression can be better observed are in Supplementary Fig.
S1. These data are discussed in the paragraph "Clinical
significance of hERG1 in gastric cancer." Western blot
experiments performed in some of the samples collected
confirmed IHCdata (Supplementary Fig. S2). To strengthen
these results, hERG1 expression was evaluated in the whole
set of samples by IHC using both an anti C-terminus
(intracellular) polyclonal antibody (16) and a monoclonal
antibody recognizing anextracellular epitope (17). As better
analyzed below (see paragraph "Clinical significance of
hERG1 in gastric cancer") more than 60% of the samples
displayed a high hERG1 immunoreactivity.
We also performed RQ-PCR experiments in order to
evaluate whether the altered hERG1 expression in tumor
samples correlated with an altered hERG1 mRNA level.
RQ-PCR also allowed us to discriminate between the 2
hERG1 transcripts, hERG1A and hERG1B (19). Figure 2A
shows RQ-PCR data relative to the hERG1A transcript,
obtained in a subset of the collected specimens (n ¼ 28).
Data are expressed as folds of expression, compared with
the corresponding normal mucosa. The hERG1A tran-
script showed a variable expression and was expressed
at high levels in roughly 50% of gastric cancer samples.
However, the hERG1B transcript was never expressed at
levels comparable or higher than the normal mucosa
(Supplementary Fig. S3).
To gain insights on the genetic mechanisms underlying
hERG1A overexpression in gastric cancer, we performed
molecular analyses using different gastric cancer cell lines
as a model. As shown in Fig. 2B, the hERG1A transcript was
expressed in all the gastric cancer cell lines, although at
variable levels, from more than 100 folds (AKG cells) to
nihil (AGS cells; Fig. 2B). No expression of the hERG1B
isoform was detected in any of the gastric cancer cell lines
tested (not shown; ref. 12). These results were confirmed
by Western Blots performed on membrane extracts (see
Supplementary Fig. S4). Moreover, a typical IhERG was
recorded in those cell lines with a significant hERG1
expression. A representative example, relative to KATO III
cells, is reported in Fig. 2C. As a whole, 2 of the 4 examined
gastric cancer cell lines showed high hERG1 expression,
with a percentage mimicking results obtained in gastric
cancer primary samples.
We also analyzed pre- and posttranslational mechanisms
that could underlie the different hERG1A expression in
gastric cancer cells and primary samples. The relevance of
posttranslational mechanisms was excluded, because no
differences in the amount of the hERG1USO protein (ref. 20;
e.g., the main posttranslational mechanism affecting
hERG1 protein levels) were detected (Supplementary Fig.
S5). We then analyzed the methylation status in a subset of
gastric cancer primary samples (n¼ 13). To this purpose, 7
samples expressing (see asterisks in Fig. 2D) and 6 nonex-
pressing the hERG1A transcript were analyzed, looking at 2
CpG islands, 1 located within the promoter and 1 adjacent
to the TSS. As shown in Fig. 2D, primary samples showed a
variable methylation status of the CpG island inside the
hERG1A promoter that was independent from the
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expression of the hERG1A gene. However, the CpG island
located at the hERG1A TSS turned out to be homogeneously
unmethylated, a fact that suggests a constitutively active
promoter in all the samples tested. As a whole, the meth-
ylation levels of the 2 CpG islands analyzed does not seem
to explain the different hERG1A levels in gastric cancer
primary samples.
We then studied hERG1A mRNA stability, quantifying
hERG1A mRNA by RQ-PCR after actinomycin D (ActD)
addition. These experiments were performed on the 2 cell
lines expressing hERG1 at the highest (AKG) and at the
lowest (AGS) levels. After exposure to ActD for either 2 or 6
hours, a greater amount of hERG1AmRNA is detectable in
AKGcomparedwithAGS cells (Fig. 2E).Hence, an increased
mRNA stability (witnessed by a slower rate ofmRNA decay)
could underlie the hERG1A overexpression in gastric cancer
cell lines. This finding could be translated to gastric cancer
primary samples.
hERG1 channels drive VEGF-A secretion in gastric
cancer
We then evaluated the functional role of hERG1 channels
in gastric cancer cells. In particular, we analyzed whether a
functional link between hERG1 and VEGF-A existed in
gastric cancer. All the gastric cancer cell lines under study
secreted VEGF-A in the culture medium, as determined by
ELISA test, but only those with a significant hERG1 expres-
sion (AKG and KATO III) secreted high levels of the protein
(see histograms in Fig. 3A).
VEGF-A secretion turned out to bemodulated by hERG1,
as shown by data obtained either inhibiting hERG1 activity
(through specific blockers) or reducing its expression
(through siRNAs). Note that hERG1 blockers had no over-
lapping effects on hERG1 expression (Supplementary Table
S4). Indeed, the addition of either WAY or E4031 signifi-
cantly decreased VEGF-A secretion in AKG and KATO III
cells (Fig. 3B), whereas had no effect in MKN28 and AGS
Figure 1. hERG1 protein expression
in primary gastric cancer samples.
IHC was performed on gastric
cancer samples and paired healthy
mucosa. A and B, staining of
normal lining mucosa and fundic
cells. Some of gastric gland cells
(i.e., parietal cells) show a strong
expression of hERG1 protein
(see arrows) in striking contrast
to the lining epithelium. C,
microphotograph of a
representative sample of the
intestinal type showing a strong
hERG1 expression in the
cytoplasm and on plasma
membrane. D, representative IHC
performed on a sample of Lauren's
diffuse type, negative for hERG1
expression. E–H, hERG1
expression in gastric cancer
samples of different TNM stage
and grading. Four representative
microphotographs are reported,
showing hERG1 expression
(evaluated with polyclonal
antibody) in samples classified as
TNM IA and IV, G2, and G3 as
indicated in the pictures.
Magnification, #20.
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cells. However, tetraethylammonium (TEA), a wide inhib-
itor of Kþ channels (proven not to affect hERG1 at the
concentration used in these experiments), had no effect on
VEGF-A secretion (Fig. 3B). To decrease hERG1 expression,
3 different anti-hERG1 siRNAs (a-siRNAs 1–3) were tested,
all effective in reducing hERG1 expression (Supplementary
Table S5). All the a-siRNAs significantly decreased VEGF-A
secretion in AKG and KATO III (Fig. 3B). The inhibitory
effect of a-siRNAs was identical to that obtained with an
anti(a)-VEGF-A siRNA (see the last right column relative to
AKG and KATO III cells in Fig. 3B).
The decrease of VEGF-A secretion produced by hERG1
inhibition depended on a negative regulation of VEGF-A
transcription. In fact, a-hERG1 siRNAs tested either sepa-
rately (on AKG cells; Supplementary Table S4), ormixed (in
both AKG and KATO III cell lines; Fig. 3C), decreasedVEGF-
A expression. The effects of a-hERG1 siRNAs were not
because of off-target effects, because the expression of a
completely unrelated transcript, Kv1.3 (which encodes for a
voltage-dependent Kþ channel, often expressed in cancer
cells) was totally unaffected by a-hERG1 siRNAs (Supple-
mentary Table S5). Moreover, the inhibition of VEGF-A
expression produced by silencing hERG1 channels was
similar to that obtained by either blocking hERG1 activity
with WAY or silencing VEGF-A through a-VEGF-A siRNA
(Supplementary Table S5).
VEGF-A expression is mainly controlled by the activity of
the transcription factor HIF, whose "a" subunit is under
control of either O2 tension or intracellular signaling path-
ways (21). We recently reported that VEGF-A transcription
in colorectal cancer cells was controlled by a peculiar
signaling pathway triggered by the hERG1/b1 integrin com-
plex, centered on Akt and converging on the regulation of
the 2HIF-a transcripts:HIF-1a andHIF-2a (22). Hence, we
tested whether the same pathway was controlled by hERG1
in gastric cancer cells. We first determined the transcrip-
tional activity of HIF in gastric cancer cells. HIF activity
(measured as luciferase activity, see Supplementary Data)
was decreased by either E4031 or WAY (Fig. 3D). However,
it increased after switching the cells to hypoxia, as expected.
HIF activity was also measured quantifying the expression
levels of HIF-1a–dependent and HIF-2a–dependent genes.
hERG1 inhibition decreased the expression of HIF-1a and
HIF-2a coregulated (GLUT-1), as well as of HIF-2a
Figure 2. hERG1A characterization
in primary gastric cancer and cell
lines. A, hERG1A transcript
expression in gastric cancer
primary samples. Graph, data
obtained by RQ-PCR analysis
performed in 28 primary gastric
cancer samples and paired healthy
mucosa. The detailed procedure is
reported in Supplementary Data.
Data are normalized on a pool of
healthy mucosal samples and
hERG1A expression is reported as
folds of control. B, expression of
hERG1A in gastric cancer cell lines.
In the histogram, data obtained
from all the experiments performed
on different gastric cancer cell
lines are summarized. C,
electrophysiological traces
registered in KATO III cells. The
biophysical profile shows the
presence of the hERG1 current.
D, RT-PCR results relative to the
methylation status of hERG1A
promoter (top) and TSSCpG island
(bottom). Experiments were
performed as detailed in
Supplementary Data. Asterisks
indicate hERG1-expressing
samples. E, RQ-PCR experiments
performed on AKG and AGS
samples treated or not with
Actinomycin D (5 mg/mL, after
overnight starvation) to inhibit
mRNA transcription. Data, means
$ SEM of 3 separate experiments,
each carried out in duplicate.
%%, P < 0.02; %%%, P < 0.01
(Student t test).
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regulated (ANGPTL-4) genes, whereas did not affect the
expression of a gene (LDHA), whose transcription only
depends on HIF-1a (Fig. 3E). Collectively, these data indi-
cate that hERG1 activity modulates mainly HIF-2 transcrip-
tional activity. Consistently, hERG1 blocking significantly
reduced the levels ofHIF-2a transcript (Fig. 3F). HIF activity
was also inhibited by 2 different PI3K/Akt inhibitors
LY294002 (LY) and perifosine (Fig. 3D), which also signif-
icantly decreased VEGF-A secretion (Supplementary Fig.
S6). We then measured both Akt activity (by an in vitro
kinase assay using GSK-3 as a substrate; Fig. 3G, left), and
Akt phosphorylation (Fig. 3G, right): both were decreased
by hERG1 inhibitors.
On the whole, in gastric cancer cells, hERG1 channels
regulate VEGF-A secretion through an Akt-dependent mod-
ulation of HIF (mainly HIF-2) transcriptional activity.
Clinical significance of hERG1 in gastric cancer
hERG1 expression was then correlated with clinico-
pathological parameters as well as with patients’ survival
in the whole cohort of gastric cancer samples, collected
from different Italian centers (see Materials and Meth-
ods). From the 579 patients initially considered for the
study, 71 were excluded because of incomplete follow up.
As shown in Supplementary Table S6, the group of 71
patients excluded from analysis did not significantly differ
Figure 3. Characterization of
hERG1 expression and VEGF-A
expression and secretion in gastric
cancer cell lines: the effects of
hERG1 inhibition or
overexpression on VEGF-A
secretion. A, VEGF-A secretion in
gastric cancer cell lines. In the
histogram, data obtained from all
the experiments performed on
gastric cancer cell lines are
summarized. B, the effect of
hERG1 blocking on VEGF-A
secretion in gastric cancer cells.
Ion channel blockers were added
24 hours before VEGF-A
measurement. hERG1 inhibitors
were used as in ref. 10. Data from 4
different experiments, each carried
out in duplicate, are reported as
mean $ SEM. TEA data refer to 2
experiments, each carried out in
triplicate. C, VEGF-A expression in
control and hERG1-silenced KATO
III and AKG cells. D, normoxic HIF-
1a transcriptional activity in AKG
cell lines in control conditions and
after hERG1A or PI3K/Akt
pharmacologic blocking. Hypoxic
HIF-1a transcriptional activity was
also shown as control. E, fold
induction of HIF(s) target genes
after hERG1 pharmacologic
blocking, GLUT1, glucose
transporter 1; ANGPTL-4,
angiopoietin-like 4; LDHA, lactate
dehydrogenase. F, HIF-2a
dependent expression after hERG1
pharmacologic blocking. G, effects
of the hERG1blocker E4031 on Akt
activity (left) and on Akt
phosphorylation (right) in AKG and
KATO III cell lines. Akt activity was
evaluated using the Akt Kinase
Assay Kit (Cell Signaling) following
the manufacturer's instructions.
Data, means $ SEM of 2 or 3
separate experiments. %, P < 0.05
(Student t test). %, P < 0.05;
%%, P < 0.02; %%%, P < 0.01
(Student t test).
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from the study population. Patient samples encompassed
all TNM stages, with higher percentages in stages III and
IV. A slight prevalence of males and G3 pathologic grade
characterized the casistic under study (Supplementary
Table S6). Moreover, 63.8% of the samples were classified
as Lauren intestinal type, which is the most frequent
histotype in Italy (23).
All the antibodies were previously validated and negative
controls were included in each IHC experiments (a repre-
sentative picture is reported in Supplementary Fig. S7). For
hERG1 expression analyses, data obtained with the hERG1
polyclonal antibody were used (representative pictures are
reported in the Supplementary Fig. S8, taking into account 2
scoring groups: lower or higher than50%(seeMaterials and
Methods in Supplementary Data).
hERG1 was expressed by 69.1% of the samples. hERG1
positivity was more evident in Lauren intestinal type gastric
cancer compared with the diffuse type (see also Fig. 1C and
D), a finding corroborated by the statistical analysis (P <
0.0001; Table 1). Moreover, hERG1 correlated with tumor
localization (P ¼ 0.017) with a prevalence in the fundus,
tumor grading, with a prevalence in G1–G2 (P < 0.001; see
also panels in Fig. 1) and with the TNM stage (P ¼ 0.031).
hERG1 positivity was higher in stages I and II (Table 1
and Fig. 1E–H). Finally, a strong correlation with VEGF-A
emerged (P < 0.001). Often the 2 proteins were coexpressed
in the same tissue sample and,more specifically, in the same
cancerous epithelial cells, with a similar pattern of expres-
sion (see Supplementary Fig. S9).
After amedianfollowupof11.1years (InterquartileRange,
IQR¼7.3–15.0), 391deathswereobserved.At theunivariate
analyses, age >70 years, male sex, site (gastric stump and
linitis plastica), advanced stages and diffuse/mixed Lauren
were associated with a worse prognosis (Table 2). The mul-
tivariate analysis confirmed the results obtained at the uni-
variate analysis (Table 2).No clinically significant interaction
emerged between hERG1 expression and the clinical and
pathologic parameters (Supplementary Fig. S10). Evaluating
the T, N, and M parameters, heterogeneity emerged within T
stage (P < 0.001, test for interaction). In particular, the
interaction analysis showed a statistically significant interac-
tion on overall survival (OS) between T stage and hERG1
expression(HR¼1.51T1,HR¼0.87T2,HR¼1.02T3,HR¼
0.64 T4). Hence, we can argue that hERG1 might display a
negative prognostic impact in T1 stage patients.
Effects of hERG1 pharmacologic targeting: in vivo
experiments
Finally, we determined whether hERG1 channels could
represent good targets for antineoplastic therapy in gastric
cancer. To test this possibility, we analyzed immunode-
ficient, athymic nu/nu mice subcutaneously injected with
hERG1-expressing gastric cancer cells, either AKG or KATO
III. In a first set of experiments,micewere injectedwith AKG
cells and treatedwith thehERG1 inhibitor E4031, daily for 2
weeks starting from the day after inoculum. The masses
obtained were then analyzed 5 days after the suspension of
treatment E4031 significantly decreased tumor growth, as
evidenced by the decrease of the tumor volume (from277.3
to 19.6mm3, P < 0.05; Fig. 4A). This effect was paralleled by
a significant decrease of tumor angiogenesis, witnessed by
intratumoral total vascular area (Fig. 4B). Moreover, vessels
within the masses obtained from control, untreated mice
were numerous, distinctly small andmore homogeneous in
calibre (lane "Control" on the right of Fig. 4C), whereas
those within the masses from E4031-treated mice were
fewer although longer (lane "E4031" on the right of Fig.
4C), with a higher perivascular fibrosis (see the arrow in
right). The reduced vasculature of gastric cancer masses of
E4031-treated mice was accompanied by a reduction of the
expression of VEGF-A and pAkt (Fig. 4C), strongly confirm-
ing in vitro findings.
Another set of in vivo experiments was then performed,
injecting KATO III cells and treating the mice when tumor
masses reached the volume of 60 mm3. In these experi-
ments, mice were treated with either E4031 or the anti–
VEGF-A antibody (bevacizumab), as single or combined
treatments. Tumor growth was inhibited by each of the
single treatments as well as by the combination of the 2
Table 1. Association between hERG1
expression and clinical and pathologic variables
Variable
hERG1
positivity
rate OR (95% CI) P
All cases 69.1% — —
Age, y
<70 69.3% 1 (ref.) 0.927
&70 68.9% 0.98 (0.67–1.44)
Gender
Male 69.1% 1 (ref.) 0.979
Female 69.0% 1.00 (0.67–1.47)
Site of primary tumor
Antrum, cardias 64.8% 1 (ref.) 0.017
Body 68.7% 1.19 (0.75–1.88)
Fundus 80.4% 2.23 (1.30–3.82)
Gastric stump,
linitis plastica
61.1% 0.85 (0.39–1.84)
TNM stage
I 75.3% 1 (ref.) 0.031
II 79.8% 1.30 (0.61–2.75)
III 65.0% 0.61 (0.33–1.14)
IV 65.3% 0.62 (0.33–1.17)
Pathologic grading
G1, G2 80.9% 1 (ref.) <0.001
G3, G4 62.3% 0.39 (0.25–0.61)
Lauren type
Intestinal 79.0% 1 (ref.) <0.001
Diffuse 53.4% 0.30 (0.20–0.47)
Mixed 47.2% 0.24 (0.13–0.43)
VEGF-A status
Negative 25.6% 1 (ref.) <0.001
Positive 75.2% 9.31 (3.61–24.0)
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agents (Fig. 4D, left). After completing the treatment sched-
ule, tumors started to grow again, except in the combined
treatment regimen. In particular, when monitored after 10
days of treatment suspension, the mean volume of tumor
masses of mice treated with E4031 þ bevacizumab was
significantly lower than those of mice treated with a single
treatment regimen (Fig. 4E). Moreover, strong inhibition of
tumor angiogenesis (in this case better witnessed by a
decrease of the number of CD34-positive tumor vessels)
was observed in masses of mice that underwent the com-
bined treatment (Fig. 4F).
Discussion
This study investigates the functional role and clinical
significance of hERG1 potassium channels in gastric cancer.
It provides evidence that hERG1 channels are overexpressed
at early stages of gastric cancer progression and regulate
VEGF-A secretion in gastric cancer. These and other findings
support the targeting of hERG1 as a possible patient-tai-
lored antiangiogenic approach in the therapy of gastric
cancer.
hERG1 channels turned out to be overexpressed in both
primary gastric tumors and gastric cancer cell lines, whereas
they were not expressed in the lining epithelium of normal
gastric mucosa. In normal stomach samples, we found a
high hERG1 IHC positivity in parietal cells of the gastric
glands, which indeed express several types of ion channels.
In particular, KCNQ1 Kþ channels are expressed on the
apical membrane of gastric parietal cells, in conjunction
with the accessory beta subunit, KCNE2. The KCNQ1/
KCNE2 complex is functional and contribute to acid secre-
tion (24, 25). Although the role of hERG1 channels in
gastric parietal cells was out of the scope of our study, it
is possible to speculate that they also could be functional in
these cells, becauseKCNE2behaves also as hERG1accessory
subunit (26).
The hERG1 expressionwe found in gastric cancer primary
samples and cell lines confirms previous data (12, 13).
Moreover, we showed that hERG1 is overexpressed and this
relies on a higher amount of the hERG1 transcript (about 20
times more) in neoplastic than in normal gastric mucosa.
Particularly, we showed that (i) only the full length hERG1A
Table 2. Univariate andmultivariate evaluation of prognostic role for OS of clinical and pathologic variables
Univariate analysis Multivariate analysis
Variable HR (95% CI) P HR (95% CI) P
Age, y
<70 1 (ref.) <0.001 1 (ref.) <0.001
&70 1.63 (1.34–1.99) 2.29 (1.86–2.82)
Gender
Male 1 (ref.) 0.012 1 (ref.) 0.004
Female 0.77 (0.62–0.95) 0.73 (0.59–0.91)
Site of primary tumor
Antrum, cardias 1 (ref.) <0.001 1 (ref.) 0.028
Body 1.14 (0.89–1.47) 1.03 (0.80–1.33)
Fundus 1.37 (1.06–1.76) 1.18 (0.90–1.54)
Gastric stump, linitis plastica 2.52 (1.67–3.80) 1.96 (1.28–3.00)
TNM stage
I 1 (ref.) <0.001 1 (ref.) <0.001
II 2.17 (1.40–3.38) 2.33 (1.48–3.66)
III 4.05 (2.70–6.08) 4.53 (2.97–6.91)
IV 7.09 (4.68–10.7) 8.42 (5.41–13.1)
Pathological grading
G1, G2 1 (ref.) 0.207 1 (ref.) 0.051
G3, G4 1.14 (0.93–1.41) 0.77 (0.59–1.00)
Lauren type
Intestinal 1 (ref.) <0.001 1 (ref.) 0.006
Diffuse 1.55 (1.23–1.94) 1.44 (1.07–1.94)
Mixed 1.79 (1.30–2.45) 1.74 (1.20–2.51)
VEGF-A status
Negative 1 (ref.) 0.510 1 (ref.) 0.575
Positive 1.00 (0.59–1.68) 0.91 (0.62–1.32)
hERG1 status
Negative 1 (ref.) 0.726 1 (ref.) 0.119
Positive 0.96 (0.78–1.19) 1.22 (0.95–1.57)
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transcript is overexpressed, a finding completely different
from what occurs in other tumors, such as leukemias
(11, 19), where only the hERG1B transcript is overex-
pressed. This suggests the existence of a tumor type–
related hERG1 isoform signature; (ii) hERG1A overexpres-
sion in gastric cancer correlates with an increased stability
of the corresponding mRNA, in highly hERG1 expressing
gastric cancer cells, a fact that candidates this as the
mechanism underlying hERG1A overexpression in gastric
cancer samples. Consistently, we excluded a significant
contribution to hERG1 overexpression by the methyla-
tion status of the hERG1A promoters as well as of post-
translational mechanisms, based on the expression of the
USO transcripts (20).
The overexpression of hERG1 in gastric cancer is wit-
nessed by a strong immunostaining of gastric cancer
samples. In this study, we used 2 different anti-hERG1
antibodies: a polyclonal antibody directed against the
intracellular C-terminus of the hERG1 protein and a
monoclonal antibody, directed against the S5-P extracel-
lular loop. The 2 sets of experiments gave comparable
results, although the concordance was not complete. For
mere technical reasons (e.g., the possibility of a lower
immunoreactivity of the monoclonal antibody to gastric
cells), we favored the use of the polyclonal antibody,
whose results well fitted with those obtained measuring
hERG1A transcript levels by RQ-PCR (Supplementary Fig.
S11).
Figure4. hERG1channels in gastric cancer as novel therapeutic targets: in vivo experiments. A, volumeof tumormasses obtained after injection of AKGcells in
control (white bar, 277.3 $ 85 mm3; 246,25 $ 0.095 mm3) and E4031-treated mice (black bar, 19.6 $ 14.5 mm3; 103,75 $ 0,05 mm3). Data, mean of 2
experiments (4 animals/group) $ SEM. B, microvessel density evaluation in tumor masses from Control and E4031-treated mice after injection
of AKG cells. Total vascular area wasmeasured as in ref. 11 after staining with an anti-CD34 antibody and is reported as mm2 per microscopic field. In Control
mice, the number of vessels was higher, although not significantly, than in E4031-treated mice (21.6 $ 2.0 vs. 15.1 $ 2.3). As concerning total
vascular area, a statistically significant difference emerged between Control and E4031-treated mice (10185.8 $ 1180.8 vs. 7829.4 $ 1148.0). C, histologic
analysis of CD34, VEGF-A, and pAkt staining of tumormasses obtained in control and E4031-treatedmice after injection of AKG cells. Bar, 200 mm (for CD34)
and 100 mm (for VEGF-A and pAkt). For quantification, positively stained cells were counted in 5 randomly selected fields under a magnification
of #400. In Control mice, the percentage of VEGF-A positive cells was higher than in treated animals (45% vs. 20%) and the same occurred for pAkt
immunostaining (55% vs. 5%). D–F, mice inoculated with KATO III cells. D, time course of tumor masses growth in the 4 different groups. Treatment
schedule is reported below. E, histogram showing tumor volumes of the explanted masses. Control mice, 162 $ 18; E4031-treated animals, 37.25 $ 5;
bevacizumab-treated mice, 24.3 $ 0.3; mice treated with bevacizumab þ E4031, 8.2 $ 2.3. Data, mean $ SEM. %, P < 0.05; %%, P < 0.02; %%%, P < 0.01
(Student t test). F, histogramshowingmicrovessel number in tumormasses fromControl and treatedmice after injection ofKATO III cells. Controlmice, 20$1;
E4031-treated animals, 13.5 $ 1.5; bevacizumab-treated mice, 6 $ 0.1; mice treated with bevacizumab þ E4031, 1.5 $ 1.5. Data, mean $ SEM.
%, P < 0.05; %%, P < 0.02 (Student t test).
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The functional role of hERG1 channels in gastric cancer
was analyzed in gastric cancer cell lines and we provided
evidence that hERG1 regulates VEGF-A transcription and
hence VEGF-A secretion in gastric cancer. Hence, hERG1
function in gastric cancer is similar to that discovered in
brain tumors (10) and during mouse colorectal carcino-
genesis (27). The regulation of VEGF-A secretion occurs
exclusively in gastric cancer cells expressing hERG1 at high
levels, a fact proven by both pharmacologic and biomolec-
ular hERG1 inhibition. Moreover, such regulation can be
traced back to a signaling mechanism triggered by hERG1
and ending into the regulation of HIF transcriptional activ-
ity (22). Interestingly, it takes place in normoxic condition
when HIF is usually rapidly degraded (21). Moreover, in
gastric cancer, the hERG1-dependent pathway mainly
impacts ontoHIF-2a and the transcription ofHIF-2–depen-
dent genes (such as ANGPTL4, besides VEGF-A), more than
of HIF-1–dependent genes, which are mainly related to cell
metabolism.We can conclude that, in gastric cancer, hERG1
behaves as a cell-cycle device, capable of regulating cell
proliferation (12, 13), as well as a progression-related gene,
mainly involved in the regulation of tumor angiogenesis.
Although the impact of hERG1 on cell cycle could be traced
back to the regulation of intracellular Ca2þ levels as a
consequenceof ahERG1-dependent regulationof themem-
brane potential value (28), the effects on tumor progression
could be related to the hERG1-dependent effect on cell
signaling, well documented in several types of cancer (3,
4, 29). This latter ability makes hERG1 not only a canonical
ion channel, but also amembrane protein able to influence
the expression of tumor-related genes in an unconventional
manner. Moreover, the specific impact of hERG1 on HIF-2
regulation in normoxia could put the bases for the devel-
opment of novel therapeutic strategies.
Finally, we evaluated the clinical significance of hERG1
expression in gastric cancer, studying a large Italian cohort
of 508 gastric cancer patients, encompassing different TNM
stages. hERG1 expression strongly correlated with intestinal
Lauren’s histologic type, tumor localization, grading (main-
ly G1–G2) and TNM stage, with a prevalence in stages I and
II. The high hERG1 expression in G1–G2 samples well
agreeswith its prevailing expression in intestinal type gastric
cancers,which are usuallywell-differentiated tumors.More-
over, the fact that hERG1 is expressed in a significant
percentage of TNM stages I and II, suggests that the over-
expression of the channel is an early event during gastric
cancer progression. This is different from what occurs in
colorectal cancers (16, 17) and fromwhat reported by Shao
and colleagues (14) andDing and colleagues (15) in gastric
cancer. The latter discrepancy could be traced back to the
fact that both studies were performed on Asian patients’
cohorts, which have different clinico-pathological charac-
teristics comparedwith non-Asian ones (30), and by the use
of different antibodies and scoring systems. The significant
early expression of hERG1 during gastric cancer progression
shown by us, is further strengthened by the statistically
significant interaction on OS between hERG1 expression
and T. In particular, we showed that hERG1 has a negative
prognostic impact in T1 patients, a finding that could be
exploited for treatment stratification of gastric cancer
patients. In fact, as a final goal, we demonstrated that
hERG1 channels might represent a pharmacologic target.
In particular, we showed that treatment of tumor-bearing
mice with a specific hERG1 blocker (E4031) decreased both
the tumor volume and intratumoral angiogenesis. Both
parameters were even more inhibited when E4031 was
added in combination with the VEGF-A antibody (bevaci-
zumab; ref. 31), with a schedule that was able to maintain
tumor inhibition even after treatment suspension. There-
fore, the blocking of hERG1 through noncardiotoxic block-
ers (either existing, as in ref. 32, or under development;
www.blackswanpharma.com) could be proposed as a com-
bination treatment able to overcome the well-known resis-
tance to antiangiogenesis treatments in solid cancers (33).
On the whole, our findings suggest the possibility of
including hERG1 channels into biomolecular panels of
gastric cancer prognosticmarkers, in the near future. Further
studies are needed to validate hERG1 impact on clinical
course or response to chemotherapy, to design a personal-
ized treatment combining noncardiotoxic hERG1 blockers
and antiangiogenesis drugs in hERG1-positive patients.
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